Literature DB >> 10220746

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study.

J Okano1, G Shiota, H Kawasaki.   

Abstract

BACKGROUND: Hepatocyte growth factor (HGF) is a potent mitogen for hepatocytes in vivo as well as in vitro. Serum levels of HGF vary in liver diseases, reflecting liver damage and dysfunction. However there are no studies reporting expression of HGF and HGF receptor (c-met protein) simultaneously in various liver diseases.
METHODS: To clarify the clinical significance of HGF/c-met protein expression in liver diseases, liver tissues from 62 patients consisting of 7 with acute hepatitis (AH), 20 with chronic hepatitis (CH), 9 with liver cirrhosis (LC) and 26 with hepatocellular carcinoma (HCC) were immunohistochemically examined.
RESULTS: Intense staining of HGF was observed in patients from AH, CH and LC, although no immunoreactivity was seen in HCC. The expression of c-met protein was higher in patients with HCC and AH than in those with CH (p < 0.05). A correlation of immunoreactivity between HGF and c-met protein was not observed expect in patients with LC (p < 0.01). The extent of c-met expression had no correlation with differentiation of HCC, tumour size, presence of portal invasion, or serum AFP levels.
CONCLUSION: The results of the present study suggest that HGF plays an important role in human liver diseases, mostly in a manner independent of c-met protein expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220746     DOI: 10.1111/j.1478-3231.1999.tb00025.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  20 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study.

Authors:  Zhi Li Wang; Ping Liang; Bao Wei Dong; Xiao Ling Yu; De Jiang Yu
Journal:  J Gastrointest Surg       Date:  2007-10-18       Impact factor: 3.452

3.  Distribution of nitric oxide synthase in normal and cirrhotic human liver.

Authors:  Lance McNaughton; Lakshmi Puttagunta; Maria Angeles Martinez-Cuesta; Norm Kneteman; Irvin Mayers; Redwan Moqbel; Qutayba Hamid; Marek W Radomski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 4.  Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

5.  Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3.

Authors:  Chen Ling; Yuan Lu; Jasmine K Kalsi; Giridhara R Jayandharan; Baozheng Li; Wenqin Ma; Binbin Cheng; Samantha W Y Gee; Katherine E McGoogan; Lakshmanan Govindasamy; Li Zhong; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

6.  Hepatic expression of hepatocyte growth factor gene mRNA in acute liver failure.

Authors:  P Harrison; C Gove; A Bomford
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

7.  Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases.

Authors:  Claudia Paternostro; Ezio David; Erica Novo; Maurizio Parola
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

Review 8.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

Review 9.  The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.

Authors:  Weon-Kyoo You; Donald M McDonald
Journal:  BMB Rep       Date:  2008-12-31       Impact factor: 4.778

10.  The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.

Authors:  Jeffrey Sum-Lung Wong; Yawen Dong; Vikki Tang; Thomas Leung; Cynthia S Y Yeung; Anna Tai; Ada Law; Tracy Shum; Gerry Gin-Wai Kwok; Bryan Cho-Wing Li; Roland Leung; Joanne Chiu; Ka-Wing Ma; Wong-Hoi She; Josephine Tsang; Tan-To Cheung; Thomas Yau
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.